Loading clinical trials...
Loading clinical trials...
Prevalence and Risk Factors for Persistent Tobacco or Alcohol Use Over the First Year of a First Lung or Head and Neck Cancer
This is an multicenter study for preventive and therapeutic strategies for patients with head and neck cancer
Continuing the chronic intoxication by either tobacco or alcohol after the initial diagnosis of a first lung or head and neck cancer significantly improves the risk of experiencing a second cancer, and largely affects the long term survival. Addiction intervention programs should be personalized according to the patient's profile, with the aim to develop more sustained intervention and monitoring in patients identified at higher risk of not spontaneously stopping harmful substance use. As of today, the trajectories of smoking and drinking habits and the risk factors for persisting smoking or drinking habits have been insufficiently explored among patients with a first lung or head and neck cancer. The ALTAK study aims to depict the rate of tobacco smokers 12 months after the initial diagnosis of a first lung or head and neck cancer. The secondary objectives of the study are: * to depict the rate of alcohol users 12 months after the initial diagnosis of a H\&N cancer * to depict the rate of tobacco smokers at cancer diagnosis * to depict the rate of alcohol users at cancer diagnosis * to determine the social, motivational, psychiatric, tobacco-related, alcohol-related, and cannabis-related features associated with stopping tobacco in the year following the diagnosis of a first TARC. * to determine the social, psychiatric, tobacco-related, alcohol-related, and cannabis-related features associated with stopping alcohol drinking in the year following the diagnosis of a first H\&N cancer
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Centre Hospitalier Régional et Universitaire - Hopital CALMETTE
Lille, France
Centre Hospitalier Régional et Universitaire - Hopital HURIEZ
Lille, France
Oscar Lambret Center
Lille, France
Start Date
April 1, 2012
Primary Completion Date
September 1, 2013
Completion Date
September 1, 2014
Last Updated
March 16, 2026
385
ACTUAL participants
physician assessment
BEHAVIORAL
Lead Sponsor
Centre Oscar Lambret
Collaborators
NCT07486219
NCT06305754
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT07485114